April 2026
Monthly Archives
More stories
-
Trending
Breakthrough in Cancer Treatment FDA Approves First Interchangeable Biosimilar for HER2 Positive Breast Cancer
FDA Approval of Poherdy: A Game Changer for HER2+ Breast Cancer Treatment The recent FDA approval of Poherdy, the first interchangeable biosimilar to Perjeta for patients with HER2-positive breast cancer, has stirred both excitement and cautious optimism among medical professionals and patient communities alike. This landmark decision promises to expand access to targeted therapies while […] More